Morris MJ - Search Results

1

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.

Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, Carbone E, Barnett ES, Hullings M, Hechtman JF, Zehir A, Shia J, Jonsson P, Stadler ZK, Srinivasan P, Laudone VP, Reuter V, Wolchok JD, Socci ND, Taylor BS, Berger MF, Kantoff PW, Sawyers CL, Schultz N, Solit DB, Gopalan A, Scher HI. Abida W, et al. Among authors: morris mj. JAMA Oncol. 2019 Apr 1;5(4):471-478. doi: 10.1001/jamaoncol.2018.5801. JAMA Oncol. 2019. PMID: 30589920 Free PMC article.

2

Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.

Morris MJ, Tong WP, Cordon-Cardo C, Drobnjak M, Kelly WK, Slovin SF, Terry KL, Siedlecki K, Swanson P, Rafi M, DiPaola RS, Rosen N, Scher HI. Morris MJ, et al. Clin Cancer Res. 2002 Mar;8(3):679-83. Clin Cancer Res. 2002. PMID: 11895895 Clinical Trial.

3

HER-2 profiling and targeting in prostate carcinoma.

Morris MJ, Reuter VE, Kelly WK, Slovin SF, Kenneson K, Verbel D, Osman I, Scher HI. Morris MJ, et al. Cancer. 2002 Feb 15;94(4):980-6. Cancer. 2002. PMID: 11920466 Free article. Clinical Trial.

4

Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer.

Morris MJ, Akhurst T, Osman I, Nunez R, Macapinlac H, Siedlecki K, Verbel D, Schwartz L, Larson SM, Scher HI. Morris MJ, et al. Urology. 2002 Jun;59(6):913-8. doi: 10.1016/s0090-4295(02)01509-1. Urology. 2002. PMID: 12031380

5

Novel therapies for the treatment of prostate cancer: current clinical trials and development strategies.

Morris MJ, Scher HI. Morris MJ, et al. Surg Oncol. 2002 Jun;11(1-2):13-23. doi: 10.1016/s0960-7404(02)00006-3. Surg Oncol. 2002. PMID: 12031864 Review.

6

Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustine.

Morris MJ, Santamauro J, Shia J, Schwartz L, Vander Els N, Kelly K, Scher H. Morris MJ, et al. Urology. 2002 Dec;60(6):1111. doi: 10.1016/s0090-4295(02)01921-0. Urology. 2002. PMID: 12475686 Review.

7

Clinical approaches to osseous metastases in prostate cancer.

Morris MJ, Scher HI. Morris MJ, et al. Oncologist. 2003;8(2):161-73. doi: 10.1634/theoncologist.8-2-161. Oncologist. 2003. PMID: 12697941 Free article. Review.

8

Optimizing targeted therapy and developing novel outcome measures for patients with advanced prostate cancer at Memorial Sloan-Kettering Cancer Center.

Morris MJ, Scher HI. Morris MJ, et al. Crit Rev Oncol Hematol. 2003 Jun 27;46 Suppl:S21-31. doi: 10.1016/s1040-8428(03)00061-1. Crit Rev Oncol Hematol. 2003. PMID: 12850524 Review.

9

Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer.

Morris MJ, Pandit-Taskar N, Divgi C, Larson S, Scher HI. Morris MJ, et al. Curr Oncol Rep. 2004 May;6(3):222-9. doi: 10.1007/s11912-004-0053-y. Curr Oncol Rep. 2004. PMID: 15066234 Review.

10

High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.

Morris MJ, Smaletz O, Solit D, Kelly WK, Slovin S, Flombaum C, Curley T, Delacruz A, Schwartz L, Fleisher M, Zhu A, Diani M, Fallon M, Scher HI. Morris MJ, et al. Cancer. 2004 May 1;100(9):1868-75. doi: 10.1002/cncr.20185. Cancer. 2004. PMID: 15112267 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

837 results

Search Page